Endothelial dysfunction in children with chronic kidney disease

Background and Objective: Cardiovascular disease (CVD) is the main cause of death in children with chronic kidney disease (CKD). Inflammation and endothelial dysfunction (ED) are found in the majority of these patients and are factors associated to CVD. Flow mediated dilatation (FMD) is a surrogate...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Juan Antonio García-Bello, Rita A. Gómez-Díaz, Alicia Contreras-Rodríguez, Lorena Sánchez-Barbosa, Rafael Mondragón-González, Juan Manuel Gallardo-Montoya, Niels H. Wacher
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Disfunción endotelial Dilatación mediada por flujo Enfermedad cardiovascular Enfermedad renal crónica Diseases of the genitourinary system. Urology RC870-923
Acceso en línea:	https://doaj.org/article/06ceab3ce8ed45a69e8886da5d7b3d70
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:06ceab3ce8ed45a69e8886da5d7b3d70
record_format	dspace
spelling	oai:doaj.org-article:06ceab3ce8ed45a69e8886da5d7b3d702021-11-14T04:31:45ZEndothelial dysfunction in children with chronic kidney disease2013-251410.1016/j.nefroe.2020.10.002https://doaj.org/article/06ceab3ce8ed45a69e8886da5d7b3d702021-07-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2013251421000833https://doaj.org/toc/2013-2514Background and Objective: Cardiovascular disease (CVD) is the main cause of death in children with chronic kidney disease (CKD). Inflammation and endothelial dysfunction (ED) are found in the majority of these patients and are factors associated to CVD. Flow mediated dilatation (FMD) is a surrogate marker validated for evaluating ED. Our objective was to identify risk factors associated to ED in children with CKD. Materials and Methods: Children 2–16 years of age were studied. Clinical information and biochemical variables were gathered, including intact parathyroid hormone (iPTH), interleukins 6 and 1b, high sensitivity C reactive protein (hsCRP), reduced glutathione, nitric oxide, malondialdehyde and homocysteine. FMD was measured, and considered altered if <7%. Results: Included were 129 patients aged 13.1 ± 2.6 years. FMD < 7% was found in 69 (52.7%). Patients with altered FMD had higher levels of triglycerides and hsCRP than those with normal FMD (145.5 mg/dl vs. 120.0 mg/dl, P = .042, y 1.24 U/L vs. 0.55 U/L, P = .007, respectively), as well as higher frequency of low iPTH (19.1% vs. 4.9%, P = .036). Levels of hsCRP correlated significantly with FMD (Rho = −0.28, P = .003). Patients with low iPTH (OR = 4.41, 95%CI 1.13–17.27, P = .033) and increased hsCRP (OR = 2.89, 95%CI 1.16–7.17, P = .022) had higher adjusted risk of having FMD < 7%. Conclusions: Hypertriglyceridemia, inflammation and low iPTH associated significantly with altered FMD. They are frequent, treatable risk factors for CVD. Resumen: Antecedentes y Objetivo: La enfermedad cardiovascular (ECV) es la principal causa de muerte en niños con Enfermedad Renal Crónica (ERC). La inflamación y la disfunción endotelial (DE) se presenta en la mayoría de estos pacientes y son factores asociados a ECV. La dilatación mediada por flujo (DMF) <7% es un marcador subrogado validado en la evaluación de la DE. Nuestro objetivo fue identificar los factores de riesgo asociados a DE en niños con ERC. Materiales y Métodos: Se estudió a niños de 2–16 años de edad. Se recopiló su información clínica y variables bioquímicas, incluidos Hormona Paratiroidea Intacta (iPTH), interleucinas 6 y 1b, Proteína C Reactiva de alta sensibilidad (hsCRP), Glutatión reducido, óxido nítrico, malondialdehído, y homocisteína. Se consideró DMF alterada <7%. Resultados: Se incluyó a 129 pacientes con edad de 13.1 ± 2.6 años. Tuvieron DMF < 7% 69 (52.7%). Los pacientes con DMF < 7% tuvieron niveles más altos de triglicéridos y de hsCRP que aquellos con DMF ≥ 7% (145.5 mg/dl vs. 120.0 mg/dl, P = .042, y 1.24 U/L vs. 0.55 U/L, P = .007, respectivamente), así como una mayor frecuencia de iPTH baja (19.1% vs. 4.9%, P = .036). Los niveles de hsCRP se correlacionaron significativamente con la DMF (Rho = −0.28, P = .003). Los pacientes con iPTH baja (OR = 4.41, 95% CI 1.13–17.27, P = .033) y con hsCRP incrementada (OR = 2.89, 95%CI 1.16–7.17, P = .022) tuvieron un riesgo ajustado mayor de DMF < 7%. Conclusiones: La hipertrigliceridemia, la inflamación e iPTH baja se asociaron significativamente a una DMF alterada. Son factores de riesgo de ECV frecuentes y tratables.Juan Antonio García-BelloRita A. Gómez-DíazAlicia Contreras-RodríguezLorena Sánchez-BarbosaRafael Mondragón-GonzálezJuan Manuel Gallardo-MontoyaNiels H. WacherElsevierarticleDisfunción endotelialDilatación mediada por flujoEnfermedad cardiovascularEnfermedad renal crónicaDiseases of the genitourinary system. UrologyRC870-923ENNefrología (English Edition), Vol 41, Iss 4, Pp 436-445 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Disfunción endotelial Dilatación mediada por flujo Enfermedad cardiovascular Enfermedad renal crónica Diseases of the genitourinary system. Urology RC870-923
spellingShingle	Disfunción endotelial Dilatación mediada por flujo Enfermedad cardiovascular Enfermedad renal crónica Diseases of the genitourinary system. Urology RC870-923 Juan Antonio García-Bello Rita A. Gómez-Díaz Alicia Contreras-Rodríguez Lorena Sánchez-Barbosa Rafael Mondragón-González Juan Manuel Gallardo-Montoya Niels H. Wacher Endothelial dysfunction in children with chronic kidney disease
description	Background and Objective: Cardiovascular disease (CVD) is the main cause of death in children with chronic kidney disease (CKD). Inflammation and endothelial dysfunction (ED) are found in the majority of these patients and are factors associated to CVD. Flow mediated dilatation (FMD) is a surrogate marker validated for evaluating ED. Our objective was to identify risk factors associated to ED in children with CKD. Materials and Methods: Children 2–16 years of age were studied. Clinical information and biochemical variables were gathered, including intact parathyroid hormone (iPTH), interleukins 6 and 1b, high sensitivity C reactive protein (hsCRP), reduced glutathione, nitric oxide, malondialdehyde and homocysteine. FMD was measured, and considered altered if <7%. Results: Included were 129 patients aged 13.1 ± 2.6 years. FMD < 7% was found in 69 (52.7%). Patients with altered FMD had higher levels of triglycerides and hsCRP than those with normal FMD (145.5 mg/dl vs. 120.0 mg/dl, P = .042, y 1.24 U/L vs. 0.55 U/L, P = .007, respectively), as well as higher frequency of low iPTH (19.1% vs. 4.9%, P = .036). Levels of hsCRP correlated significantly with FMD (Rho = −0.28, P = .003). Patients with low iPTH (OR = 4.41, 95%CI 1.13–17.27, P = .033) and increased hsCRP (OR = 2.89, 95%CI 1.16–7.17, P = .022) had higher adjusted risk of having FMD < 7%. Conclusions: Hypertriglyceridemia, inflammation and low iPTH associated significantly with altered FMD. They are frequent, treatable risk factors for CVD. Resumen: Antecedentes y Objetivo: La enfermedad cardiovascular (ECV) es la principal causa de muerte en niños con Enfermedad Renal Crónica (ERC). La inflamación y la disfunción endotelial (DE) se presenta en la mayoría de estos pacientes y son factores asociados a ECV. La dilatación mediada por flujo (DMF) <7% es un marcador subrogado validado en la evaluación de la DE. Nuestro objetivo fue identificar los factores de riesgo asociados a DE en niños con ERC. Materiales y Métodos: Se estudió a niños de 2–16 años de edad. Se recopiló su información clínica y variables bioquímicas, incluidos Hormona Paratiroidea Intacta (iPTH), interleucinas 6 y 1b, Proteína C Reactiva de alta sensibilidad (hsCRP), Glutatión reducido, óxido nítrico, malondialdehído, y homocisteína. Se consideró DMF alterada <7%. Resultados: Se incluyó a 129 pacientes con edad de 13.1 ± 2.6 años. Tuvieron DMF < 7% 69 (52.7%). Los pacientes con DMF < 7% tuvieron niveles más altos de triglicéridos y de hsCRP que aquellos con DMF ≥ 7% (145.5 mg/dl vs. 120.0 mg/dl, P = .042, y 1.24 U/L vs. 0.55 U/L, P = .007, respectivamente), así como una mayor frecuencia de iPTH baja (19.1% vs. 4.9%, P = .036). Los niveles de hsCRP se correlacionaron significativamente con la DMF (Rho = −0.28, P = .003). Los pacientes con iPTH baja (OR = 4.41, 95% CI 1.13–17.27, P = .033) y con hsCRP incrementada (OR = 2.89, 95%CI 1.16–7.17, P = .022) tuvieron un riesgo ajustado mayor de DMF < 7%. Conclusiones: La hipertrigliceridemia, la inflamación e iPTH baja se asociaron significativamente a una DMF alterada. Son factores de riesgo de ECV frecuentes y tratables.
format	article
author	Juan Antonio García-Bello Rita A. Gómez-Díaz Alicia Contreras-Rodríguez Lorena Sánchez-Barbosa Rafael Mondragón-González Juan Manuel Gallardo-Montoya Niels H. Wacher
author_facet	Juan Antonio García-Bello Rita A. Gómez-Díaz Alicia Contreras-Rodríguez Lorena Sánchez-Barbosa Rafael Mondragón-González Juan Manuel Gallardo-Montoya Niels H. Wacher
author_sort	Juan Antonio García-Bello
title	Endothelial dysfunction in children with chronic kidney disease
title_short	Endothelial dysfunction in children with chronic kidney disease
title_full	Endothelial dysfunction in children with chronic kidney disease
title_fullStr	Endothelial dysfunction in children with chronic kidney disease
title_full_unstemmed	Endothelial dysfunction in children with chronic kidney disease
title_sort	endothelial dysfunction in children with chronic kidney disease
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/06ceab3ce8ed45a69e8886da5d7b3d70
work_keys_str_mv	AT juanantoniogarciabello endothelialdysfunctioninchildrenwithchronickidneydisease AT ritaagomezdiaz endothelialdysfunctioninchildrenwithchronickidneydisease AT aliciacontrerasrodriguez endothelialdysfunctioninchildrenwithchronickidneydisease AT lorenasanchezbarbosa endothelialdysfunctioninchildrenwithchronickidneydisease AT rafaelmondragongonzalez endothelialdysfunctioninchildrenwithchronickidneydisease AT juanmanuelgallardomontoya endothelialdysfunctioninchildrenwithchronickidneydisease AT nielshwacher endothelialdysfunctioninchildrenwithchronickidneydisease
_version_	1718429938289213440

Endothelial dysfunction in children with chronic kidney disease

Ejemplares similares